Dena R Ramey Selected Research

oxidized low density lipoprotein

7/2017	Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial.
1/2016	Gender Disparities in Lipid-Lowering Therapy in Cardiovascular Disease: Insights from a Managed Care Population.
4/2015	Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
1/2014	Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
1/2014	Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
9/2013	Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting.
1/2013	Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
11/2010	Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patients.
3/2010	Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients.
1/2008	Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dena R Ramey Research Topics

Disease

8	Coronary Disease (Coronary Heart Disease) 01/2014 - 01/2006
5	Cardiovascular Diseases (Cardiovascular Disease) 07/2017 - 09/2013
3	Hypercholesterolemia 07/2017 - 01/2008
3	Vascular Diseases (Vascular Disease) 01/2014 - 03/2010
2	Rheumatoid Arthritis 11/2022 - 05/2005
2	Atherosclerosis 07/2017 - 01/2006
2	Diabetes Mellitus 09/2013 - 01/2008
1	Atherosclerotic Plaque (Atheroma) 12/2011
1	Peripheral Arterial Disease 12/2011
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2006
1	Sitosterolemia 01/2006
1	Osteoarthritis 05/2005
1	Ankylosing Spondylitis 05/2005
1	Hemorrhage 05/2005
1	Peptic Ulcer (Peptic Ulcers) 05/2005

Drug/Important Bio-Agent (IBA)

10	oxidized low density lipoproteinIBA 07/2017 - 01/2008
9	LDL CholesterolIBA 07/2017 - 03/2010
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2014 - 01/2008
4	CholesterolIBA 04/2015 - 01/2006
3	Simvastatin (Zocor)FDA LinkGeneric 07/2017 - 01/2008
3	LipidsIBA 01/2016 - 11/2010
2	Biomarkers (Surrogate Marker)IBA 07/2017 - 12/2011
2	Ezetimibe (Zetia)FDA Link 07/2017 - 01/2008
1	etanercept biosimilar SB4IBA 11/2022
1	Etanercept (Enbrel)FDA Link 11/2022
1	Biosimilar PharmaceuticalsIBA 11/2022
1	Toll-Like Receptors (Toll-Like Receptor)IBA 12/2011
1	Messenger RNA (mRNA)IBA 12/2011
1	CytokinesIBA 12/2011
1	Triglycerides (Triacylglycerol)IBA 01/2008
1	Proteins (Proteins, Gene)FDA Link 01/2008
1	SterolsIBA 01/2008
1	Atorvastatin (Lipitor)FDA Link 01/2008
1	gamma-sitosterol (beta-sitosterol)IBA 01/2006
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 05/2005
1	EtoricoxibIBA 05/2005

Therapy/Procedure

7	Therapeutics 01/2016 - 01/2008
1	Secondary Prevention 01/2016